Modality
Degrader
MOA
BiTE
Target
ALK
Pathway
RAS/MAPK
Ewing Sarcoma
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
May 2020
→ Jan 2026
Phase 1Current
NCT07292453
1,120 pts·Ewing Sarcoma
2020-05→2026-01·Not yet recruiting
NCT03830842
1,209 pts·Ewing Sarcoma
2022-11→TBD·Recruiting
2,329 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-133mo agoInterim· Ewing Sarcoma
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P1
Not yet…
P1
Recruit…
Catalysts
Interim
2026-01-13 · 3mo ago
Ewing Sarcoma
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07292453 | Phase 1 | Ewing Sarcoma | Not yet recr... | 1120 | ORR |
| NCT03830842 | Phase 1 | Ewing Sarcoma | Recruiting | 1209 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BII-8315 | Biogen | NDA/BLA | CDK2 |